Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.

Second, in terms of ECOG PS status, there was a nonsignificant trend toward worse ECOG PS and a higher number of LNs positive (ECOG 0 = 0.82, ECOG 1 = 1.84, ECOG 2 = 2.5, P = .08) Next, we looked at age and ECOG PS with regards to pathological treatment response.

also in 5,406 other papers